期刊
FUTURE MICROBIOLOGY
卷 9, 期 4, 页码 523-542出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fmb.14.18
关键词
Aspergillus fumigatus; azoles; Candida albicans; Cryptococcus neoformans; drug resistance; echinocandins; polyenes
类别
资金
- Canadian Institutes of Health Research (CIHR)
- CIHR
- Ontario Graduate Scholarship
- Canada Research Chair in Microbial Genomics and Infectious Disease
- Ministry of Research and Innovation Early Researcher Award
- Natural Sciences & Engineering Research Council Discovery Grant [355965]
- CIHR grants [MOP-86452, MOP-119520]
Fungal pathogens cause life-threatening infections in immunocompetent and immunocompromised individuals. Millions of people die each year due to fungal infections, comparable to the mortality attributable to tuberculosis or malaria. The three most prevalent fungal pathogens are Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. Fungi are eukaryotes like their human host, making it challenging to identify fungal-specific therapeutics. There is a limited repertoire of antifungals in clinical use, and drug resistance and host toxicity compromise the clinical utility. The three classes of antifungals for treatment of invasive infections are the polyenes, azoles and echinocandins. Understanding mechanisms of resistance to these antifungals has been accelerated by global and targeted approaches, which have revealed that antifungal drug resistance is a complex phenomenon involving multiple mechanisms. Development of novel strategies to block the emergence of drug resistance and render resistant pathogens responsive to antifungals will be critical to treating life-threatening fungal infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据